PMID- 35951144 OWN - NLM STAT- MEDLINE DCOM- 20221028 LR - 20221028 IS - 1617-4623 (Electronic) IS - 1617-4615 (Print) IS - 1617-4623 (Linking) VI - 297 IP - 6 DP - 2022 Nov TI - Increased expression of Myosin X contributes to the metastasis in patients with laryngeal squamous cell carcinoma. PG - 1529-1536 LID - 10.1007/s00438-022-01934-x [doi] AB - Laryngeal Squamous Cell Carcinoma (LSCC) is one of the most common malignancy in Head and neck cancer for which the mechanism underlying its metastasis is poorly understood. Myosin X, a molecular motor in cells has been demonstrated to play an important role in cell migration. However, whether Myosin X is involved in the metastasis of LSCC remains unclear. To investigate the expression of Myosin X and its implication in the metastasis of LSCC, we recruited 30 patients with LSCC and 6 patients with vocal cord polyp range from October 2016 to October 2018. Tissue samples were obtained during surgery and the expression of Myosin X, Cortactin, MMP2, MMP9, E-cadherin, and beta-catenin in tissue samples were evaluated by RT-PCR, Western blot, immunohistochemistry or ELISA. Patients with LSCC were further followed-up 2 year after surgery for metastasis analysis. We found that the level of Myosin X, Cortactin, MMP2, and MMP9 was much higher in poorly differentiated LSCC compared to that in moderately and highly LSCC, as well as the control tissues. In contrast, the expression of epithelial-mesenchymal transition related marker, E-cadherin, and beta-catenin, were much lower in poorly differentiated LSCC tissues compared to that in moderately and highly differentiated LSCC tissues, as well as the control tissues. Moreover, the expression of Myosin X was positively correlated with Cortactin, MMP2, and MMP9 levels. Increased expression of Myosin X in LSCC tissues was related to higher risk of metastasis. In conclusion, our findings showed that. Myosin X augments the expression of Cortactin, MMP2 and MMP9, which could upregulate the cell migration and the matrix degradation, and consequently reduce the expression of E-cadherin and beta-catenin, thereby activating epithelial-mesenchymal transformation and promoting the metastasis of LSCC. Targeting Myosin X may have potential therapeutic effect in the metastasis of LSCC. CI - (c) 2022. The Author(s). FAU - Deng, Gang AU - Deng G AD - Department of Otolaryngology-Head and Neck Surgery, Wuhan No.1 Hospital, Wuhan, People's Republic of China. FAU - Fu, Tie-Jun AU - Fu TJ AD - Department of Otolaryngology-Head and Neck Surgery, Shiyan Hospital of Integrated Traditional and Western Medicine, Shiyan, People's Republic of China. FAU - Liu, Cui-Ping AU - Liu CP AUID- ORCID: 0000-0002-7003-6784 AD - Department of Otolaryngology-Head and Neck Surgery, Second People's Hospital of Gansu Province, No. 1 He Zheng West Street, Chengguan District, Lanzhou, 730000, Gansu, People's Republic of China. lcping2021@163.com. LA - eng GR - 2017CFB758/Natural Science Foundation of Hubei Province/ PT - Journal Article DEP - 20220811 PL - Germany TA - Mol Genet Genomics JT - Molecular genetics and genomics : MGG JID - 101093320 RN - 0 (beta Catenin) RN - 0 (Cadherins) RN - 0 (Cortactin) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) RN - EC 3.6.4.1 (Myosins) SB - IM MH - Humans MH - beta Catenin/genetics/metabolism MH - Cadherins/genetics/metabolism MH - Cell Line, Tumor MH - Cortactin/metabolism MH - Gene Expression Regulation, Neoplastic MH - *Laryngeal Neoplasms/genetics MH - Lymphatic Metastasis MH - Matrix Metalloproteinase 2/metabolism MH - Matrix Metalloproteinase 9/genetics/metabolism MH - *Myosins/metabolism MH - *Squamous Cell Carcinoma of Head and Neck/genetics PMC - PMC9596522 OTO - NOTNLM OT - Epithelial-mesenchymal transition OT - Laryngeal squamous cell carcinoma OT - MMP OT - Metastasis OT - Myosin X COIS- The authors declare no conflict of interest. EDAT- 2022/08/12 06:00 MHDA- 2022/10/28 06:00 PMCR- 2022/08/11 CRDT- 2022/08/11 11:21 PHST- 2021/11/01 00:00 [received] PHST- 2022/07/23 00:00 [accepted] PHST- 2022/08/12 06:00 [pubmed] PHST- 2022/10/28 06:00 [medline] PHST- 2022/08/11 11:21 [entrez] PHST- 2022/08/11 00:00 [pmc-release] AID - 10.1007/s00438-022-01934-x [pii] AID - 1934 [pii] AID - 10.1007/s00438-022-01934-x [doi] PST - ppublish SO - Mol Genet Genomics. 2022 Nov;297(6):1529-1536. doi: 10.1007/s00438-022-01934-x. Epub 2022 Aug 11.